Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Estradiol Transdermal System USP, 0.014 mg/day, the company announced through an exchange filing.
Estradiol transdermal system is indicated for prevention of postmenopausal osteoporosis. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
Estradiol Transdermal System USP, 0.014 mg/day (weekly) had annual sales of USD 1.9 mn in the United States (IQVIA MAT Feb. 2023).
The group now has 363 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Mumbai News: SHRC Seeks Reports From BMC, Police After Stray Dog Attack On Watchman In Andheri Housing Society
Navi Mumbai News: Animal Welfare Officer Urges Action Against Illegal Slaughterhouses Near NMIA After Ahmedabad Plane Crash
'If You Are Good Friends...': Rishabh Pant Reflects On His Special Bond With Shubman Gill Ahead Of ENG Vs IND Test Series; Video
Banita Sandhu Says She Was Body-Shamed, Reveals Being Called 'Ugly': 'They Said I Was Too Skinny To Be Attractive'
